BioNTech (BNTX) Competitors

BioNTech (NASDAQ:BNTX) and GSK (NYSE:GSK) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, community ranking, valuation, media sentiment, profitability and risk.

Does the media prefer BNTX or GSK?

In the previous week, GSK had 5 more articles in the media than BioNTech. MarketBeat recorded 22 mentions for GSK and 17 mentions for BioNTech. BioNTech's average media sentiment score of 1.03 beat GSK's score of 0.79 indicating that BioNTech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	7 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
GSK	10 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

Which has more risk & volatility, BNTX or GSK?

BioNTech has a beta of 1.07, indicating that its stock price is 7% more volatile than the S&P 500. Comparatively, GSK has a beta of 0.56, indicating that its stock price is 44% less volatile than the S&P 500.

Is BNTX or GSK a better dividend stock?

BioNTech pays an annual dividend of $1.53 per share and has a dividend yield of 1.3%. GSK pays an annual dividend of $1.60 per share and has a dividend yield of 4.3%. BioNTech pays out -51.0% of its earnings in the form of a dividend. GSK pays out 100.6% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.

Which has higher earnings & valuation, BNTX or GSK?

GSK has higher revenue and earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$2.75B	10.26	$1.01B	-$3.00	-39.23
GSK	$31.38B	2.46	$3.29B	$1.59	23.49

Do insiders & institutionals believe in BNTX or GSK?

15.5% of BioNTech shares are owned by institutional investors. Comparatively, 15.7% of GSK shares are owned by institutional investors. 19.2% of BioNTech shares are owned by company insiders. Comparatively, 10.0% of GSK shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Does the MarketBeat Community favor BNTX or GSK?

GSK received 679 more outperform votes than BioNTech when rated by MarketBeat users. Likewise, 57.14% of users gave GSK an outperform vote while only 46.93% of users gave BioNTech an outperform vote.

Company	Underperform	Outperform
BioNTech	Outperform Votes 145 46.93%	Underperform Votes 164 53.07%
GSK	Outperform Votes 824 57.14%	Underperform Votes 618 42.86%

Do analysts recommend BNTX or GSK?

BioNTech currently has a consensus price target of $143.44, indicating a potential upside of 21.89%. GSK has a consensus price target of $40.58, indicating a potential upside of 8.64%. Given BioNTech's stronger consensus rating and higher probable upside, research analysts plainly believe BioNTech is more favorable than GSK.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	0 Sell rating(s)	3 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.89
GSK	0 Sell rating(s)	8 Hold rating(s)	0 Buy rating(s)	3 Strong Buy rating(s)	2.55

Is BNTX or GSK more profitable?

GSK has a net margin of 8.13% compared to BioNTech's net margin of -15.16%. GSK's return on equity of 48.59% beat BioNTech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-15.16%	-2.35%	-2.05%
GSK	8.13%	48.59%	11.11%

Summary

GSK beats BioNTech on 13 of the 21 factors compared between the two stocks.